QuidelOrtho (QDEL) Earnings Date & Reports

Key Takeaways

• QuidelOrtho reported third-quarter 2026 revenue of $618.9 million, down 11.6% year over year and below Wall Street consensus estimates.
• Adjusted earnings per share (EPS) of $0.31 came in ahead of analyst expectations, which ranged from roughly $0.18 to $0.20.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $148 million, reflecting a 23.9% margin.
• Management launched a new cost transformation and enterprise restructuring program aimed at improving profitability and cash flow.
• Full-year 2026 guidance was maintained in a range of $0.65–$0.90 for adjusted EPS and $2.52 billion–$2.60 billion for revenue.
• You can explore more about this ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• For automated trade ideas and market insights, check out Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

QuidelOrtho's third-quarter report arrives at a pivotal moment for the diagnostics leader. The company has been navigating a weaker respiratory testing season, ongoing distributor-sales disruption in China tied to proposed pricing guidelines, and pressure from the Middle East conflict. These headwinds have weighed on the Point of Care and Labs segments, even as the Immunohematology business has shown resilience. Investors are closely watching whether management's new restructuring program can stabilize margins and cash flow while recent product launches — including a High-Sensitivity Troponin assay and the VITROS 450 platform — begin to contribute. The quarter offers a key test of the company's ability to defend profitability amid declining revenue.

Reported Results

For the third quarter ended September 27, 2026, QuidelOrtho reported total revenue of $618.9 million, an 11.6% decline from the prior-year period and below consensus estimates of roughly $628 million to $635 million. On a constant-currency basis, revenue also fell 11.6%.

Adjusted diluted EPS was $0.31, exceeding analyst expectations of approximately $0.18 to $0.20. Adjusted EBITDA came in at $148 million, representing a 23.9% margin and narrowly ahead of the consensus estimate of about $145 million. GAAP (Generally Accepted Accounting Principles) operating margin was negative 1.2%, an improvement from negative 101% in the same quarter last year.

Management reiterated full-year 2026 guidance for adjusted EPS of $0.65 to $0.90 and revenue of $2.52 billion to $2.60 billion, with midpoints roughly in line with, or slightly below, consensus. The company also introduced a cost transformation and enterprise restructuring program designed to improve profitability and free cash flow.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking earnings movers like QuidelOrtho or searching for new setups across sectors, the AI Screener offers a streamlined way to narrow the field.

Market Reaction and Investor Sentiment

QuidelOrtho shares fell sharply following the release, dropping roughly 10.6% to about $12.63 immediately after results. The negative reaction reflected investor disappointment over the top-line miss and cautious full-year guidance, despite the adjusted EPS beat. The stock has been under sustained pressure over the past year, and the latest report reinforced concerns about declining demand, particularly in respiratory testing and China-related distributor sales. Investors appeared to focus on the revenue shortfall and the broader restructuring announcement rather than the profitability beat, underscoring lingering uncertainty around the pace of the company's turnaround.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch how quickly QuidelOrtho's newly announced cost transformation and enterprise restructuring program translates into improved margins and cash flow. Management has framed the initiative as a way to evolve the operating model around the distinct needs of its customers, but the financial impact and any associated charges remain key items to track in coming quarters.

Demand signals will also be critical. The China market remains a source of uncertainty as the company awaits final guidelines from the China National Health Security Administration (NHSA) on in vitro diagnostics (IVD) pricing. Any clarification on implementation timelines could materially affect the Labs segment's trajectory.

Finally, product-launch execution and the pace of the respiratory testing cycle will shape near-term results. The U.S. rollout of the High-Sensitivity Troponin assay and the international expansion of the VITROS 450 platform are potential catalysts, while the Immunohematology segment's growth offers a more stable foundation. Balancing these factors against ongoing cost pressures will be central to the company's story in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations